TORNTPHARM
Torrent Pharmaceuticals Limited
NSELast Traded Price
₹4410.8
-110.8 (-2.45%)
Open
₹4554.8
High
₹4575
Low
₹4356.1
Prev Close
₹4537.8
Industry
Pharmaceuticals
Market Cap
149525.20 Cr
Filing History
Recent corporate announcements and filings for TORNTPHARM
Business Update
Neutral
2026-05-30 10:49
Torrent Pharmaceuticals Limited announced the schedule for its upcoming investor meetings. Company representatives will participate in the BoFA 2026 India Conference on June 3, 2026, and Citi's 2026 India Conference on June 4, 2026. Both events will be held in Mumbai and will include group and one-on-one meetings.
Business Update
Neutral
2026-05-27 17:26
Torrent Pharmaceuticals Limited has informed the exchanges that the transcript of its conference call with analysts and investors on the audited financial results for the quarter and year ended 31st March, 2026, has been placed on the company's website.
Business Update
Neutral
2026-05-22 20:02
Torrent Pharmaceuticals Limited announced the availability of the audio recording of its conference call with analysts/investors on the audited financial results for the quarter and year ended March 31, 2026. The recording has been placed on the company's website.
Financials
Positive
2026-05-22 17:08
Torrent Pharmaceuticals Limited has fixed Friday, May 29, 2026, as the Record Date for determining shareholders eligible for the final dividend for the year 2025-26, if declared.
Financials
Positive
2026-05-22 16:57
Torrent Pharmaceuticals reported standalone Q4 FY26 Total Revenue from Operations of ₹2,735 Cr vs ₹2,433 Cr (▲12.41% YoY), EBITDA of ₹956 Cr vs ₹844 Cr (▲13.27% YoY), and PAT of ₹467 Cr vs ₹474 Cr (▼1.48% YoY). EBITDA Margin was 34.95% vs 34.69% (▲26 bps). The Board recommended a final dividend of ₹9/- (180%) per equity share and proposed an enabling approval for Qualified Institutional Placement (QIP) of up to ₹5,000 crores.
Financials
Positive
2026-05-22 16:54
Torrent Pharmaceuticals reported Consolidated Revenue of ₹4,197Cr vs ₹2,959Cr (▲41.84% YoY), EBITDA of ₹1,290Cr vs ₹940Cr (▲37.23% YoY), and PAT of ₹364Cr vs ₹498Cr (▼26.91% YoY). EBITDA Margin was 30.74% vs 31.77% (▼103bps). The decline in PAT and margin contraction is primarily due to exceptional items and increased finance costs associated with the acquisition of JB Pharma. The Board recommended a final dividend of ₹9/- per equity share and approved seeking enabling approval for a Qualified Institutional Placement (QIP) of up to ₹5,000 crores.
Financials
Positive
2026-05-22 16:52
Standalone Revenue ₹2,793Cr vs ₹2,448Cr (▲14.09% YoY), EBITDA ₹1,003Cr vs ₹868Cr (▲15.55% YoY), PAT ₹467Cr vs ₹474Cr (▼1.48% YoY). EBITDA Margin 35.98% vs 35.46% (▲52bps).
Routine
Neutral
2026-05-22 16:51
New Filing detected. See link for details.
Business Update
Neutral
2026-05-16 18:35
Torrent Pharmaceuticals Limited announced the rescheduling of its post quarterly financial result conference call with investors/analysts. The call, originally scheduled for 06:30 P.M. on May 22, 2026, to discuss the financial performance for the quarter and year ended March 31, 2026, has been moved to 05:30 P.M. on the same day. The dial-in details remain unchanged.
Routine
Neutral
2026-05-12 16:45
New Filing detected. See link for details.
Business Update
Neutral
2026-05-12 15:06
Torrent Pharmaceuticals Limited has scheduled a teleconference with investors and analysts on 22nd May, 2026, at 06:30 P.M. to discuss the financial performance of the company for the quarter and year ended 31st March, 2026. The filing includes universal and international dial-in information along with a Diamond Pass Registration link for participants.
Governance
Positive
2026-04-28 22:58
Torrent Pharmaceuticals Limited announced that its Equity Shareholders, at an NCLT convened meeting on April 28, 2026, approved the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. The resolution was passed by the requisite majority, with approximately 99.33% of shareholders (by number) voting in favour during remote e-voting and 100% during e-voting at the meeting.
Governance
Positive
2026-04-28 22:38
Torrent Pharmaceuticals Limited announced that its Equity Shareholders, at an NCLT-convened meeting held on April 28, 2026, approved the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited by requisite majority.
Governance
Positive
2026-04-28 21:07
Torrent Pharmaceuticals Limited announced that the NCLT convened meeting of its Equity Shareholders was held on April 28, 2026. During the meeting, the proposed Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited (JB Pharma) with Torrent Pharmaceuticals Limited was duly approved by the Equity Shareholders with the requisite majority.
Routine
Neutral
2026-04-10 19:08
New Filing detected. See link for details.
Business Update
Neutral
2026-03-30 20:09
Torrent Pharmaceuticals Limited sold 50,000 equity shares of UNM Foundation (an associate Section 8 company with no turnover) for ₹5,00,000 to its Holding Company, Torrent Investments Limited, on March 30, 2026. This was a related party transaction.
Routine
Neutral
2026-03-28 12:26
Torrent Pharmaceuticals Limited announced the closure of its trading window for designated persons from April 1, 2026. It will reopen 48 hours after the submission of the Audited Financial Results for the Financial Year ended March 31, 2026.
Business Update
Neutral
2026-03-28 10:44
Torrent Pharmaceuticals will hold a shareholder meeting on April 28, 2026, via Video Conferencing, to approve the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited. This meeting is pursuant to an order from the National Company Law Tribunal.
Routine
Neutral
2026-03-27 20:27
New Filing detected. See link for details.
Business Update
Neutral
2026-03-25 20:07
Torrent Pharmaceuticals informed about a Corrigendum Order issued by the NCLT on March 24, 2026, related to the proposed amalgamation with J.B. Chemicals & Pharmaceuticals Limited. The order, which pertains to a Scheme of Amalgamation, was uploaded on the NCLT website on March 25, 2026.
Business Update
Positive
2026-03-24 19:10
Torrent Pharmaceuticals Limited announced that the NCLT Ahmedabad Bench has uploaded the Order on 23rd March, 2026, regarding the first motion application for its proposed amalgamation with J.B. Chemicals & Pharmaceuticals Limited.
Business Update
Positive
2026-03-21 14:01
Torrent Pharma launched oral and injectable formulations of Semaglutide (brands Sembolic and Semalix) in India, becoming the first Indian company to offer generic oral Semaglutide at Rs. 3,999 per month. This expands its presence in the type-2 diabetes and obesity market, aiming to provide affordable treatment options.
Business Update
Neutral
2026-02-25 19:28
Torrent Pharma announced a schedule of investor meetings with institutional investors in Singapore (March 2-4), Hongkong (March 5-6), and London (March 9-12) in March 2026, as per SEBI Regulation 30.
Business Update
Neutral
2026-02-20 18:47
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter and nine months ended 31st December, 2025, has been placed on the Company's website.
Business Update
Neutral
2026-02-13 19:46
Torrent Pharmaceuticals announced that the audio recording of the conference call with analysts/investors on financial results for the quarter and nine months ended 31st December, 2025, has been placed on its website.
Financials
Positive
2026-02-13 17:12
Board approved Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2025. An interim dividend of ₹29/- (580%) per equity share was declared, payable around March 6, 2026.
Financials
Positive
2026-02-13 17:07
Standalone Revenue ₹2,591Cr vs ₹2,380Cr (▲9% YoY), EBITDA ₹992Cr vs ₹890Cr (▲11.5% YoY), PAT ₹577Cr vs ₹485Cr (▲19% YoY). EBITDA Margin 38.29% vs 37.39% (▲90bps). The board also declared an interim dividend of ₹29 per equity share.
Financials
Positive
2026-02-13 17:03
Consolidated Revenue ₹3,303Cr for Q3 FY26 vs ₹2,809Cr for Q3 FY25 (▲18% YoY).
Financials
Positive
2026-02-13 17:02
The Board approved audited standalone and unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. An interim dividend of ₹29/- (580%) per equity share was recommended, expected to be paid around March 6, 2026.
Financials
Positive
2026-02-13 17:02
The Board approved Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025. An interim dividend of ₹29/- (580%) per equity share was declared, payable around March 6, 2026.
Financials
Positive
2026-02-13 16:54
The Board approved unaudited consolidated financial results for the quarter ended December 31, 2025, and declared an interim dividend of ₹29/- (580%) per equity share of ₹5/- fully paid up, payable around March 6, 2026. Detailed financial figures were not provided in this filing.
Business Update
Positive
2026-02-11 21:42
Torrent Pharma announced its schedule for investor meetings in Mumbai. The company will participate in institutional investor meetings from Feb 16-19, 2026, the Kotak - Chasing Growth 2026 Investor Conference on Feb 23, 2026, and the IIFL - Enterprising India Investor Conference on Feb 24, 2026.
Routine
Neutral
2026-02-03 22:04
New Filing detected. See link for details.
Financials
Positive
2026-02-03 18:53
Torrent Pharmaceuticals has fixed Thursday, February 19, 2026, as the Record Date for determining shareholders eligible for an Interim Dividend, if declared by the Board on February 13, 2026.